What Makes an Attractive MedTech Acquisition: Nine Patterns from the 2026 Deal Wave

$36.5 billion in disclosed MedTech acquisitions in the first half of 2026 alone. Boston Scientific, Abbott, Medtronic, Stryker, Danaher, Johnson & Johnson. Across roughly forty transactions, patterns emerge. Actual patterns in what strategic acquirers keep paying up for. · Juan Vegarra

Over the last nine months, MedTech companies bought other MedTech companies at a pace we haven’t seen in years. PwC counted $36.5 billion in disclosed deals during the first half of 2026 alone.^[1] Boston Scientific announced a $14.5 billion acquisition of Penumbra in January. Abbott closed a $21 billion acquisition of Exact Sciences in March. Danaher agreed to acquire Masimo in February. Stryker paid up to $835 million for Amplitude Vascular Systems in April. Medtronic completed acquisitions of CathWorks ($585 million) and Scientia Vascular ($550 million). Johnson & Johnson picked up Atraverse Medical. W.L. Gore acquired Conformal Medical. Olympus agreed to acquire BioProtect for $270 million.^[2] That is the highlight reel of the disclosed deals in a year where at least as much action is happening off the public wire.

If you are a founder wondering why some MedTech companies get acquired for premium valuations while others struggle to attract strategic interest at all, the 2026 deal wave is a useful test case. When you look across dozens of transactions completed or announced this year, patterns emerge. Not marketing patterns. Not investment banker slide-deck patterns. Actual patterns in what strategic acquirers keep paying up for.

I have spent the last few months tracking these deals as part of my day job, and after pattern recognition across roughly forty transactions, nine themes keep showing up. If you are building a MedTech company, investing in one, or thinking about strategic options for one you already own, these are worth knowing.

Secret 1: Category leadership beats category entry

Almost every big 2026 acquisition was an acquirer doubling down on a category they were already in. Boston Scientific bought Penumbra to reinforce a vascular intervention franchise they already led. Medtronic bought CathWorks to strengthen coronary interventional cardiology where they were already a top player. Stryker bought AVS to extend a peripheral vascular business that already exists inside the company. Abbott bought Exact Sciences to deepen a diagnostics franchise they had been building for years.

You almost never see a big MedTech acquirer paying a premium to enter a brand new category cold. The pattern is doubling down where the acquirer already has distribution, KOL relationships, and manufacturing capabilities. If you are building a MedTech company, understand which category you are really in from the acquirer’s perspective. That determines which strategics will actually pay for you.

Secret 2: Prior partnership predicts acquisition

The Medtronic CathWorks deal is instructive. Medtronic and CathWorks signed a co-promotion agreement in 2022. Medtronic co-marketed the FFRangio system for four years before pulling the trigger on acquisition. When the ALL-RISE trial results came out at ACC 2026 showing non-inferiority to wire-based FFR across 1,900 patients at 59 sites, Medtronic exercised its option to acquire for $585 million.^[2]

This is a common pattern. Strategic acquirers frequently pilot a relationship first, verify the technology and management team through actual commercial engagement, then acquire once the evidence base and integration path are proven. If you are a founder, this means the relationship-building work you do with potential acquirers today is not sales calls. It is early diligence on both sides. The best time to start those conversations is roughly three years before you actually want to sell.

Secret 3: The sweet spot is late-stage clinical, not seed

Some 2026 deals happened pre-FDA-clearance. AVS did not have coronary IVL clearance when Stryker bought it. Conformal Medical was clinical-stage when W.L. Gore acquired it. But every “early” deal had substantial clinical evidence in hand or in flight. AVS had positive POWER PAD 2 pivotal data at VIVA 2025 and an active POWER CAD I first-in-human coronary study. Conformal Medical was in the CONFORM pivotal trial for their LAAO device.

You almost never see acquirers paying premium for pre-clinical companies with no human data. And you rarely see acquirers paying premium for commercially mature companies that have already peaked. The sweet spot is late-stage clinical or early commercial, where pivotal readouts are imminent or just completed. That is where the strategic risk is manageable and the upside is still real.

Secret 4: Differentiation must be architectural, not incremental

Look at what got acquired at premium multiples in 2026. CathWorks: AI-based angio-derived FFR, fundamentally different from wire-based FFR. AVS: CO2-generated hydraulic pressure IVL, fundamentally different from electrohydraulic or laser IVL. Conformal Medical: foam-based LAAO, fundamentally different from nitinol-frame LAAO. Penumbra: thrombectomy platforms with distinctive mechanical designs across stroke, PE, and peripheral indications.

Notice a pattern. Each acquired company had genuine architectural differentiation, not incremental improvement over an existing approach. Acquirers pay for real technical distinctiveness because it creates a defensible position in the acquirer’s portfolio. If your device is “our version of what already exists but better,” you are a commodity acquisition and you will be priced accordingly. If your device is “a different way to solve the same clinical problem,” you are a strategic acquisition and the price changes meaningfully. Sometimes by orders of magnitude.

Secret 5: Trial evidence is the fuel

Every major 2026 deal was accompanied by or timed to strong clinical evidence. CathWorks: ALL-RISE trial one-year results at ACC 2026, 1,900 patients, 59 sites, non-inferiority to wire-based FFR with reduced procedure time. Boston Scientific’s Penumbra acquisition: robust portfolio of pivotal trials across thrombectomy indications with years of registry data behind the primary products. Danaher’s Masimo target: decades of clinical validation on pulse oximetry accuracy and utility.

Even the pre-clearance deals had trial engines. AVS had POWER PAD 2 pivotal data supporting the peripheral 510(k) submission and POWER CAD I coronary feasibility just enrolling. Conformal Medical had the CONFORM pivotal trial recruiting toward FDA submission. The trial is not a nice-to-have. The trial is the fuel that lights the M&A rocket. Founders who cut corners on clinical evidence to conserve capital are optimizing for the wrong thing. Acquirers pay for evidence, not for capital efficiency.

Secret 6: Portfolio reshape drives what gets bought

Big acquirers in 2026 have been simultaneously divesting and acquiring. Teleflex spun off its OEM business to investment firms Montagu and Kohlberg for $1.5 billion in August. BD, Solventum, and Johnson & Johnson have all executed significant divestitures in 2025 and 2026. Multiple large MedTechs are shedding non-core divisions. The capital freed up is being redeployed into higher-growth categories.^[2]

This means you should understand not just what a potential acquirer does today, but what they are pruning versus what they are watering. A category the acquirer is divesting is not going to be an M&A target for them. A category the acquirer is expanding is where the money will land. Read the earnings calls. Read the investor day slides. The strategic priorities are written down if you look. Medtronic CEO Geoff Martha stating on the Q3 2026 earnings call that the company plans “upwards of another two or three billion dollars” of M&A over the next 12 to 18 months is not a mystery. That is a public roadmap for anyone building a company that could plausibly fit.^[3]

Secret 7: Tuck-in beats transformational

Medtronic CEO Geoff Martha said it explicitly on the Q3 2026 earnings call: the acquisition strategy is “close adjacency to our existing business,” in the “tuck-in” category, up to several billion dollars but many small-to-medium deals rather than one massive transformational bet.^[3]

That is most acquirers today. The lesson: if you are a MedTech founder positioning for acquisition, do not try to be the transformational bet. Be the natural tuck-in. Be the company where the acquirer’s salesforce can start selling your product on day one after close, using existing customer relationships and existing capital equipment relationships. The tuck-in has predictable synergy math. The transformational deal requires the acquirer to build new capability, which most acquirers today are not willing to do.

There is an exception. Some transformational deals do happen. Boston Scientific’s Penumbra acquisition at $14.5 billion is transformational in scale. But even Penumbra fit an existing Boston Scientific strategic priority (vascular intervention leadership) rather than opening a genuinely new category. The transformational scale was on top of a tuck-in strategic logic.

Secret 8: Consumer and workflow angles get premium multiples

Abbott paid $21 billion for Exact Sciences in part because Cologuard is a genuinely consumer-facing brand. Direct-to-patient screening, home sample collection, familiar name recognition. Danaher targeted Masimo because pulse oximetry is embedded across hospital workflows in a way that creates recurring disposable revenue. Even CathWorks was attractive partly because its software integrates into cath lab workflows without requiring new capital equipment purchases.

The pattern: MedTech that reduces distribution friction, expands consumer access, or embeds into existing workflows gets valued at premium multiples versus MedTech that requires new capital equipment purchases and new clinical training. Founders should think hard about the friction their product imposes on adoption. The lower the friction, the higher the eventual acquisition multiple. Not because friction is bad clinically, but because low-friction products scale faster once inside an acquirer’s distribution engine.

Secret 9: The regulatory environment matters

The FTC blocked Edwards Lifesciences’ proposed acquisition of JenaValve Technology in January 2026. That was a signal. Antitrust concerns in categories with limited competition are real, and both acquirers and targets are now pricing them into strategic thinking. Deals that create dominant market positions face genuine regulatory risk. Deals that add differentiated capability without creating monopoly power do not.^[2]

For founders, this affects strategic positioning. If your category has three or four viable acquirers, you have real competitive tension and premium valuations. If your category has one obvious acquirer because everyone else has been consolidated out, you may face regulatory headwinds in a deal that could otherwise happen. The optimal category structure for founders is fragmented on the acquirer side, so multiple strategics can credibly bid.

What this adds up to

Nine patterns, one underlying idea. The MedTech companies that get acquired at premium valuations in 2026 share a common shape. They are architecturally differentiated in a category their acquirer already leads. They have substantial clinical evidence in hand or in flight. They fit as a tuck-in that the acquirer’s existing salesforce can immediately monetize. They reduce distribution friction or embed into existing workflows. And they have been building relationships with potential acquirers for years before the deal announcement.

Companies that get overlooked share a different shape. They are incremental improvements in commodity categories. They lack clinical evidence quality or scale. They require the acquirer to build new capabilities, salesforce, or category presence. They impose friction on adoption. And they are strangers to the strategic community when they finally start looking for a deal.

The good news is that all nine patterns are things founders and their boards can influence deliberately. None of them are luck. Building a company that eventually gets acquired at premium valuations is a compounding discipline, not a lightning strike.

That is the map. The territory is yours to navigate.

Juan Vegarra is the author of An Outsider’s Playbook (2026). The views here are his own. More essays · Free toolkits · Advisory · Write me